U.S. Office REITs Stock News

Recent coverage has put Nomad Foods (NOMD) in focus after it received a strong value rating, with valuation ratios such as Forward P/E, P/B, P/S, and P/CF comparing favorably against industry peers. See our latest analysis for Nomad Foods. The recent focus on Nomad Foods' value credentials comes after a mixed run, with a 1 month share price return of 8.57% and year to date share price return of 6.25%, set against a 1 year total shareholder return decline of 28.81% that reflects past weakness...

Spectrum Brands Holdings (SPB) has drawn fresh attention after recent trading left the stock with a one-month return of 22% and a gain of 34.1% over the past three months, sharpening interest in its consumer brands portfolio. See our latest analysis for Spectrum Brands Holdings. That recent run sits on top of a 31.43% year to date share price return as the stock trades at US$78.91. The 1 year total shareholder return of 3.46% and 3 year total shareholder return of 33.70% suggest momentum has...

NasdaqGS:NDAQ has launched the Nasdaq Private Capital Indexes, a new suite of benchmarks for private markets. The indexes aim to provide greater transparency and standardized performance measurement for private capital investments. The launch is designed to serve institutional investors, consultants, and other market participants that use private market data. NasdaqGS:NDAQ operates as a global technology and market infrastructure provider, with data, analytics, and index services sitting...

The U.S. FDA is now reviewing Moderna’s mRNA flu vaccine application after previously issuing a Refusal to File tied to the study’s choice of comparator. This reversal reopens the regulatory path for Moderna’s mRNA flu program, which is part of the company’s broader respiratory vaccine portfolio. The shift follows public criticism of the initial decision and comes at a time when mRNA platforms remain central to Moderna’s long term product plans. For investors watching NasdaqGS:MRNA, this...

Advanced Energy Industries (NasdaqGS:AEIS) is actively pursuing acquisitions to expand its presence, with recent deals focused on industrial and medical technology. Management has highlighted a busy acquisition pipeline and points to recent integration of new technology as evidence that its inorganic growth push is gaining traction. The company is signaling that further deals in industrial and medical markets are a priority, with the goal of reshaping its portfolio around higher value...

Core & Main (CNM) has attracted fresh attention after recent share price moves, with the stock down about 6% over the past week and month, yet showing a positive total return over the past 3 months. See our latest analysis for Core & Main. While the share price is down 6.1% over the last week and 6.7% over the past month, the 90 day share price return of 16.1% and three year total shareholder return of 132.4% suggest longer term momentum has been much stronger than the recent pullback around...

Earnings trigger and why it matters for Atlas Energy Solutions stock Atlas Energy Solutions (AESI) recently reported fourth quarter and full year 2025 results, with quarterly revenue of US$249.43 million and a shift to a net loss compared with profit in the prior year period. See our latest analysis for Atlas Energy Solutions. The earnings-driven swing to a quarterly and full-year loss has been followed by a 1-day share price return of a 6.06% decline and a 7-day return of a 6.54% decline...

Cognizant Technology Solutions (CTSH) has drawn investor attention after a period of weak share performance, with returns negative over the past month, past 3 months, year to date, and past year. See our latest analysis for Cognizant Technology Solutions. The recent 6% one day share price decline, extending to a 27.38% 30 day share price return and a 26.41% 1 year total shareholder return, points to fading momentum as investors reassess growth prospects and risk. If Cognizant’s pullback has...

Catalyst Pharmaceuticals (CPRX) has been drawing attention after recent share price moves, with the stock closing at US$24.11. This has put fresh focus on how its rare disease portfolio supports the current valuation. See our latest analysis for Catalyst Pharmaceuticals. Recent trading has been relatively muted, with a 1 day share price return showing a decline of 0.78% and a 7 day share price return showing a decline of 0.90%. At the same time, a 1 month share price return of 2.25% and a...

EOG Resources (EOG) heads into its quarterly earnings announcement with investors weighing mixed analyst commentary on Texas well productivity, growing international exposure, shifting ratings, and fresh insider selling activity around the stock. See our latest analysis for EOG Resources. EOG’s share price has climbed 12.9% over the past 30 days and 16.0% over the past 90 days, even as the 1 year total shareholder return shows a 5.1% decline. This indicates recent shorter term momentum...

Zimmer Biomet Holdings stock: why investors are watching now Zimmer Biomet Holdings (ZBH) has caught investor attention after a month that included a 14.85% share price gain and annual revenue of US$8.23b, with net income of US$705.1m. See our latest analysis for Zimmer Biomet Holdings. That 14.85% 30 day share price return and 10.49% year to date share price return contrast with a 5.23% decline in 1 year total shareholder return and a 34.64% decline over 5 years. This suggests that recent...

Oshkosh (OSK) has caught investor attention after a strong run in recent months, with the share price last closing at $176.95. Here is how its recent performance and fundamentals currently stack up. See our latest analysis for Oshkosh. The recent move to $176.95 caps a strong run, with a 30-day share price return of 15% and a 90-day share price return of 38.6%, while the 1-year total shareholder return of 74.7% highlights how momentum has been building over both shorter and longer periods. If...

If you are wondering whether Atmos Energy is attractively priced at its current level, this article will walk through what the market price might be saying about the stock. The shares last closed at US$181.72, with returns of 1.4% over 7 days, 9.9% over 30 days, 7.3% year to date, 24.4% over 1 year, 70.3% over 3 years and 140.1% over 5 years. Recent investor attention has focused on Atmos Energy as a regulated utility with a long standing role in US gas distribution. This has kept it in many...

Wondering if NRG Energy at a last close of US$176.52 is still offering value, or if most of the opportunity is already on the table? This article walks through what the numbers suggest about the stock’s current pricing. NRG Energy’s share price returns are strong on recent timeframes, with 2.4% over 7 days, 18.2% over 30 days, 6.2% year to date, 72.8% over 1 year and a very large gain over 3 years that is roughly 5x, alongside 403.8% over 5 years. Recent headlines around NRG Energy have...

Zacks recently upgraded McEwen to a Rank #2 (Buy), reflecting higher earnings estimates and signaling that analysts view its underlying operations more favorably than before. This shift in analyst sentiment places McEwen among the stronger names in the Zacks universe for earnings revisions, highlighting how changing expectations can influence market attention. We’ll now examine how this Zacks Rank upgrade, driven by improved earnings estimates, may influence McEwen’s existing investment...

Opendoor Technologies (NasdaqGS:OPEN) reported a 46% sequential jump in home purchases, indicating faster acquisition activity. The company highlighted AI driven gains in pricing and underwriting efficiency under its new CEO. Management pointed to improved inventory turnover and expanded its mortgage offering as part of a broader turnaround plan. Leadership is targeting breakeven adjusted net income by 2026 alongside continued expansion into new markets. Opendoor Technologies, trading at...

If you are wondering whether Skyworks Solutions is attractively priced or just a value trap, you are in the right place for a clear, valuation focused look at the stock. The share price last closed at US$59.78, with returns of 1.4% over the past 30 days, a 7.2% decline year to date, and a 6.2% decline over the last year that longer term holders will be very aware of. Recent coverage of Skyworks has centered on its role as a key semiconductor supplier and on how demand trends across...

If you are wondering whether OFG Bancorp at around US$41.39 is still good value or already pricing in a lot of optimism, you are asking the right question. The stock has had mixed recent returns, with a 1.2% decline over the last 7 days, an 11.4% gain over 30 days, 0.9% year to date, 2.4% over 1 year, 50.3% over 3 years and 134.3% over 5 years, which can change how investors think about both upside and risk. Recent news around OFG Bancorp has focused on its position as a US regional bank and...

If you are wondering whether Coty’s share price now reflects a fair deal or a value trap, you are not alone. This article focuses squarely on what the current valuation is really telling you. The stock recently closed at US$2.59, with returns of 3.2% over 7 days, a 22.9% decline over 30 days, a 16.7% decline year to date, and a 56.8% decline over 1 year, while the 3 year and 5 year returns stand at 76.9% and 67.9% declines respectively. Recent news around Coty has focused on its brand...

In February 2026, DexCom reported past fourth-quarter 2025 results showing sales of US$1,259.6 million and net income of US$267.3 million, alongside full-year 2025 sales of US$4.66 billion and net income of US$836.3 million. The company also reiterated its 2026 revenue guidance of US$5.16–US$5.25 billion and completed a US$500.0 million share buyback that reduced its share count by nearly 2%. We’ll now consider how DexCom’s reaffirmed 2026 revenue guidance and completed buyback program may...

Day One Biopharmaceuticals (DAWN) is back in focus after the company set February 24, 2026 as the date for its Q4 2025 earnings release and accompanying conference call. See our latest analysis for Day One Biopharmaceuticals. At a share price of $11.70, Day One Biopharmaceuticals has a 90 day share price return of 24.07% and a year to date share price return of 32.20%. The 1 year total shareholder return is 3.94% lower, which indicates that more recent momentum has picked up ahead of the...

Ategrity Specialty Insurance Company Holdings (ASIC) has drawn fresh attention after a sharp recent move in its share price, with the stock up 6.1% over the past day and 32.7% in the past week. See our latest analysis for Ategrity Specialty Insurance Company Holdings. The recent surge in Ategrity Specialty Insurance Company Holdings’ share price, including a 32.7% 7 day share price return and a 23.97% 90 day share price return, suggests short term momentum is building while year to date...

Berkshire Hathaway disclosed in the fourth quarter that it acquired a little more than five million shares of The New York Times Company, while separately New York Times Advertising and Magnite previously announced an expanded collaboration making Magnite's DV+ the preferred platform for private marketplace deals for the publisher’s mobile in‑app ad supply. The combination of a high‑profile shareholder like Berkshire Hathaway and a deeper in‑app advertising partnership highlights how New...

IDEXX Laboratories (NasdaqGS:IDXX) has announced that long-serving board member M. Anne Szostak will retire following the 2026 Annual Meeting of Stockholders. The company has recently appointed Michael G. Erickson, PhD, to its Board of Directors as part of an upcoming refresh in board composition. These board changes come as IDEXX trades at a share price of $623.13 and continues to adjust its governance structure. IDEXX Laboratories, trading on the NasdaqGS under the ticker IDXX, currently...